#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Propionic acidaemia Graft versus host disease Glomerulonephritis chronic Nephroblastoma Vascular calcification Arrhythmogenic right ventricular dysplasia Pulmonary arterial hypertension Dermatitis Atypical haemolytic uraemic syndrome Myelofibrosis Pemphigus Hepato-lenticular degeneration Myelodysplastic syndrome MELAS syndrome Chronic myeloid leukaemia More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Treatment Congenital generalised lipodystrophy Synovial sarcoma – Basic Information Immunodeficiency congenital Adrenogenital syndrome – Life with Disease Stevens-Johnson syndrome – Diagnostics Bronchiolitis obliterans syndrome – Basic Information Encephalitis autoimmune Chondrosarcoma – Treatment Biotinidase deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ace Inhibitors, Plain 64CU-PSMA I&T Ammonium Chloride Lanifibranor Allo-501A Corylus Avellana L. Rosuvastatin Isosorbide Dinitrate Sodium Sulfate Anhydrous RLY-2608 Potassium Oxybate Elexacaftor Desloratadine Dabrafenib Mesylate Temozolomide Atazanavir Alternaria Alternata (402) Vincristine BENZYLPENICILLIN POTASSIUM Sulfamethoxazole More therapies…

    Learn about Your Condition

    Fallopian tube cancer stage IV Hypoalbuminaemia Ocular hypertension Albuminuria Herpes virus infection Richter's syndrome Adenomyosis Actinic keratosis Muscle injury Erdheim-Chester disease Bacteraemia Schizophrenia Aneurysm ruptured Thromboembolectomy Gallbladder cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Pembrolizumab
    Spain

  • Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    Spain

  • Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capivasertib
    • Abemaciclib
    • Palbociclib
    Belgium Denmark France Germany Italy Poland +2

  • Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Giredestrant
    • Tamoxifen
    France Spain

  • Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Epirubicin
    • Exemestane
    Spain

  • Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • ZELENECTIDE PEVEDOTIN
    Belgium France Italy Spain
Previous Page
1 … 8 9 10

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!